natgillin/translations-raw huggingface dataset:
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
One side of the tablet is debossed with the number “93”. 
Ena stran tablete ima vtisnjeno številko »93«.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed or blood in the urine. 
Krvavitve se lahko pojavijo kot krvavitve v želodec ali črevesje, modrice, hematomi (nenavadne krvavitve ali modrice pod kožo), krvavitev iz nosu ali kri v urinu.
Each film-coated tablet contains 59.05 mg of lactose (as monohydrate). 
Ena filmsko obložena tableta vsebuje 59,05 mg laktoze (v obliki monohidrata).
Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued. 
Agregacija trombocitov in čas krvavitve sta se postopoma vrnila na izhodiščno vrednost, v splošnem v 5 dneh po ukinitvi zdravljenja.
Other medicines and Clopidogrel Teva 
Druga zdravila in zdravilo Klopidogrel Teva
• Signs of liver problems such as yellowing of the skin and /or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions'). 
• Znaki jeternih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
Then, the recommended dose is one 75-mg tablet of Clopidogrel Teva per day as described above. 
Nato je priporočeni odmerek ena 75-mg tableta zdravila Klopidogrel Teva na dan, kot je opisano zgoraj.
• if you have kidney or liver disease. 
• Če imate jetrne ali ledvične bolezni.
Separate one individual blister cell from the rest of the strip by gently tearing along the perforations around it. 
Ločite posamezno pretisno celico od preostalega dela traka, tako da nežno pretrgate perforacijsko linijo okoli celice.
If you forget to take Clopidogrel Teva 
Če ste pozabili vzeti zdravilo Klopidogrel Teva
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days 
• Če se je v zadnjih sedmih dneh pri vas pojavil strdek v arteriji v možganih (ishemična kap).
What Clopidogrel Teva is and what it is used for 
Kaj je zdravilo Klopidogrel Teva in za kaj ga uporabljamo
Bottles contain 30 or 100 film-coated tablets. 
Plastenke vsebujejo 30 ali 100 filmsko obloženih tablet.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. 
Po enkratnem ali večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira.
What you need to know before you take Clopidogrel Teva Do not take Clopidogrel Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Teva Ne jemljite zdravila Klopidogrel Teva:
The most common side effect reported with Clopidogrel Teva is bleeding. 
Najpogostejši neželeni učinek, o katerem so poročali z zdravilom Klopidogrel Teva je krvavitev.
• You should tell your doctor if a surgery (including dental) is planned. 
• Zdravnika obvestite o načrtovani operaciji (tudi o zobozdravstveni).
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Varnost in učinkovitost klopidogrela so vrednotili v 5 dvojno slepih študijah, v katere je bilo vključenih več kot 88.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in ASA, v študijah CURE, CLARITY, COMMIT in ACTIVE-A pa so primerjali klopidogrel s placebom; obe zdravili pa so bolniki dobivali v kombinaciji z ASA in drugo standardno terapijo.
- a recent surgery (including dental). 
o nedaven kirurški poseg (vključno na zobeh).
Clopidogrel Teva is unlikely to affect your ability to drive or to use machines. 
Ni verjetno, da bi zdravilo Klopidogrel Teva vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
Therapeutic experience with clopidogrel is limited in patients with renal impairment. 
Ledvična okvara Terapevtske izkušnje s klopidogrelom so omejene pri bolnikih z ledvično okvaro.
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC Code: B01AC04. 
Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Teva in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Klopidogrel Teva v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
- a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body). 
o krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa).
(≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
75 mg-325 mg daily). 
(75-325 mg enkrat na dan).
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Krvavitve in hematološke motnje Zaradi tveganja krvavitve in hematoloških neželenih učinkov moramo takoj pretehtati potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadarkoli se v času zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intervali študije.
• The film-coated tablets are light pink to pink, film coated, capsule shaped tablets. 
• Filmsko obložene tablete so nežno rožnate do rožnate, v obliki kapsule.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
75 mg/dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg/dan, ne glede na starost, spol ali raso.
In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers. 
Pri slabih metabolizatorjih je bila izpostavljenost aktivnemu presnovku za 63 do71 % manjša kot pri dobrih metabolizatorjih.
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Razen tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let,
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Macrogol 4000 
Filmska obloga: laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) makrogol 4000
• Fever, signs of infection or extreme tiredness. 
• Zvišana telesna temperatura, znaki okužbe ali huda utrujenost.
For minor cuts and injuries, e.g., cutting yourself shaving, this is usually of no concern. 
Pri manjših vrezninah ali poškodbah, npr. če se urežete ali britje, to navadno ni zaskrbljujoče.
− For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
− če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; odmerka ne sme podvojiti.
If you take more Clopidogrel Teva than you should 
Če ste vzeli večji odmerek zdravila Klopidogrel Teva, kot bi smeli
In contrast, post-hoc analyses demonstrated statistically significant increases in the bleeding risk with the more potent P2Y12 inhibitors, occurring predominantly during the maintenance phase, after the first month post-ACS. 
Nasprotno pa so post hoc analize pokazale, da je z močnejšimi zaviralci P2Y12 statistično značilno večje tveganje za krvavitve; krvavitve se pojavijo pretežno med fazo vzdrževalnega zdravljenja, po prvem mesecu po
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Bolezni imunskega sistema serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)*, avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)*
Clopidogrel Teva is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Zdravilo Klopidogrel Teva jemljejo odrasli za preprečevanje nastanka krvnih strdkov (trombov) v otrdelih krvnih žilah (arterijah), proces je znan kot aterotromboza in lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
• Swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
• Otekanje ust ali bolezni kože, kot so izpuščaji, srbečica in mehurji na koži.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%). 
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3 %; IZ: 24,3 %, 57,5 %) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT=18,2 %; IZ: 6,5 %, 28,3 %).
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4). 
Zaradi tega moramo NSAIDs, vključno s COX-2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR=-4.0%; CI: -22.5 to 11.7 [p=0.639]). 
Pri bolnikih, ki so bili vključeni v preskušanje samo na podlagi nedavnega miokardnega infarkta, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT= -4,0 %; IZ: -22,5 do 11,7 [p=0,639]).
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. 
V majhnem številu primerov poročajo tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. 
NSAIDs danes nejasno, ali je povečano tveganje za gastrointestinalne krvavitve pri vseh NSAIDs.
Iron oxide red (E172) Iron oxide yellow (E172) Indigo carmine aluminium lake (E132) 
rumeni železov oksid (E172) indigo karmin barvilo (E132)
It is preferable not to take this medicine during pregnancy. 
Nosečnost in dojenje Priporočljivo je, da se tega zdravila v nosečnosti ne uporablja.
• If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
• Če se boste poškodovali ali urezali, bo potrebnega več časa za zaustavitev krvavitve.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostala (glejte poglavje
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥60 let (26 % ≥70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
Če pa vas krvavitev skrbi, nemudoma pokličite zdravnika (glejte poglavje 4 »Možni neželeni učinki«).
Contents of the pack and other information What Clopidogrel Teva contains 
Vsebina pakiranja in dodatne inforamcije Kaj vsebuje zdravilo Klopidogrel Teva
If you become pregnant while taking Clopidogrel Teva, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med uporabo zdravila Klopidogrel Teva zanosite, se nemudoma posvetujte z zdravnikom, saj se uporabo klopidogrela med nosečnostjo odsvetuje.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva. 
Iz varnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom Klopidogrel Teva ne nadaljuje.
Glomerulonephritis, blood creatinine increased 
Bolezni sečil hematurija glomerulonefritis, zvišanje kreatinina v krvi
• The active substance is clopidogrel. 
• Zdravilna učinkovina je klopidogrel.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika, preden vzamete zdravilo Klopidogrel Teva.
Calendar days Mon 
Dnevi v tednu Pon
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). 
Peroralni antikoagulansi: sočasna uporaba klopidogrela s peroralnimi antikoagulansi ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
This includes any possible side effects not listed in this leaflet. 
če opazite neželene učinke, ki niso navedni v tem navodilu.
• Adult patients suffering from acute coronary syndrome: 
• odraslih bolnikih z akutnim koronarnim sindromom;
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Teva: 
Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestite svojega zdravnika,
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Klopidogrel Teva (eno 300-mg tableto ali štiri 75-mg tablete).
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2 ali s selektivnimi zaviralci privzema serotonina (SSRI) ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve, kot je pentoksifilin (glejte poglavje 4.5).
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia 
pljučna krvavitev), bronhospazem, intersticijski pnevmonitis, eozinofilna pljučnica
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid, ki se presnavljata s CYP2C9
EU/1/09/540/008 30 film-coated tablets EU/1/09/540/009 100 film-coated tablets 
EU/1/09/540/008 30 filmsko obloženih tablet EU/1/09/540/009 100 filmsko obloženih tablet
14x1 film-coated tablets 28x1 film-coated tablets 30x1 film-coated tablets 50x1 film-coated tablets 84x1 film-coated tablets 90x1 film-coated tablets 100x1 film-coated tablets 
14x1 filmsko obložena tableta 28x1 filmsko obložena tableta 30x1 filmsko obložena tableta 50x1 filmsko obložena tableta 84x1 filmsko obložena tableta 90x1 filmsko obložena tableta 100x1 filmsko obložena tableta
How to take Clopidogrel Teva 
Kako jemati zdravilo Klopidogrel Teva
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated vegetable oil Sodium laurilsulfate 
Jedro tablete: laktoza monohidrat mikrokristalna celuloza hidroksipropilceluloza (E463) krospovidon (vrsta A) hidrogenirano rastlinsko olje natrijev lavril sulfat
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5). 
Sočasno dajanje klopidogrela s peroralnimi antikoagulansi se ne priporoča, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
Do not use this medicine after the expiry date which is stated on the outer carton, bottle or blister, after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli,
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions'). 
Vendar pa se se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
Clopidogrel Teva contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Zdravilo Klopidogrel Teva vsebuje klopidogrel in spada v skupino zdravil, imenovanih zaviralci agregacije trombocitov.
− Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
− če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa naslednji odmerek ob pravem času.
• If you suffer from severe liver disease. 
• Če imate hudo jetrno obolenje.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Teva. 
Če menite, da kaj od zgornjega velja za vas, ali če se pri vas porajajo kakršnikoli dvomi, se pred uporabo zdravila Klopidogrel Teva posvetujte z zdravnikom.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
Bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost ≥ 75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako
• Clopidogrel Teva is supplied in: 
Klopidogrel je indiciran pri:
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2.172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčno žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drugsestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
Klopidrogel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
(6,6 %) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Aluminium-aluminium peelable perforated unit-dose blisters, aluminium-aluminium perforated unit dose blisters and HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant. 
Aluminij-aluminij perforirani enoodmerni pretisni omoti z odstranljivo folijo, aluminij-aluminij perforirani pretisni omoti in HDPE plastenke z zaporkami iz polipropilena ali pred otroki varnimi zaporkami in sušilnim sredstvom, silikagelom.
What Clopidogrel Teva looks like and contents of the pack 
Izgled zdravila Klopidogrel Teva in vsebina pakiranja
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. 
− Akutni miokardni infarkt z elevacijo ST spojnice: klopidogrel je potrebno dajati v enkratnem dnevnem odmerku 75 mg, zdravljenje pa je potrebno začeti s 300 mg udarnim odmerkom v kombinaciji z ASA ter z ali brez uporabe trombolitikov.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
• Zdravnika morate nemudoma obvestiti, če se pri vas pojavi stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP), z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti,